th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando.
The Beat AML Master Clinical Trial’s innovative precision medicine approach employs comprehensive genomic profiling (CGP) to find and match specific AML genetic mutations in newly diagnosed patients over age 60 with an investigational drug or drug combination that is potentially best suited to attack the specific molecular mutations causing the cancer.
“Combining Saama’s LSAC solution with the amazing work currently in progress at Beat AML trial sites across the U.S will enhance and expedite data collection and analysis, generating insights that will inform critical decisions to accelerate the discovery of promising new AML therapies,” said Murali Krishnam, Senior Vice President of Ecosystem Innovations at Saama Technologies. “Saama is proud to welcome LLS to its partner ecosystem and further advance clinical trial conduct through our open innovation framework.”
LLS has assembled an impressive network of Beat AML® partners, including the U.S. Food and Drug Administration (FDA), top cancer centers, multiple pharmaceutical companies, a contract research organization (CRO), and select technology experts, who have united to tackle AML.
“LLS selected Saama to be part of our groundbreaking Beat AML Trial because their AI-powered LSAC solution has the ability to provide rapid insight into clinical data that will advance our study operations,” said Len Rosenberg, PhD, RPh, Head of Clinical Operations at The Leukemia & Lymphoma Society. “We look forward to the insights Saama and LSAC will add to our novel Beat AML umbrella trial, which is changing the paradigm for AML treatment and which has already yielded invaluable information in the two years since it got underway.”
More than 20,000 Americans are diagnosed with AML, the most lethal of the blood cancers, and 10,000 die from AML annually. The five-year-survival rate for older adults remains dismal at less than 20 percent. Despite advances in treating other blood cancers, the standard of treatment for AML has remained the same for more than 40 years.
“The team at The Leukemia & Lymphoma Society are pioneers when it comes to personalized medicine. Their position as a non-profit organization has allowed them to facilitate and execute a complex umbrella trial in close collaboration with a number of stakeholders,” said Kenneth L. Massey, Chief Life Science Officer at Saama Technologies. “The life science industry as a whole is counting on their success, which will hopefully be the catalyst that fundamentally changes the way clinical trials are executed. We are equally excited and humbled to be given the opportunity to be part of this landmark trial.”
Saama experts are available to discuss this new partnership and how Saama is bringing innovations in clinical trials at booth #314 during the February 18-21 SCOPE conference in Orlando.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949 and headquartered in Rye Brook, N.Y., LLS has chapters throughout the United States and Canada. To learn more, visit LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. EST.
About Saama
Saama Technologies is the advanced clinical data and analytics company, unleashing wisdom from data to deliver better business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data to deliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com.
Media Contact
Crystal Black
Saama Technologies
[email protected]
408-371-1900
The post Saama Partners With The Leukemia & Lymphoma Society to Advance Study Operations for the Beat AML Master Trial to Provide Clinical Data Analytics appeared first on Saama Technologies.
